Structured Docosahexaenoic Acid (DHA) Enhances Motility and Promotes the Antioxidant Capacity of Aged C. elegans.

Fecha de publicación: Fecha Ahead of Print:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Mora I
  • Pérez-Santamaria A
  • Arola L
  • Puiggròs F

Grupos

Abstract

The human lifespan has increased over the past century; however, healthspans have not kept up with this trend, especially cognitive health. Among nutrients for brain function maintenance, long-chain omega-3 polyunsaturated fatty acids (?-3 LCPUFA): DHA (docosahexaenoic acid) and EPA (eicosapentaenoic acid) must be highlighted, particularly structured forms of EPA and DHA which were developed to improve bioavailability and bioactivity in comparison with conventional ?-3 supplements. This study aims to elucidate the effect of a structured triglyceride form of DHA (DHA-TG) on the healthspan of aged C. elegans. Using a thrashing assay, the nematodes were monitored at 4, 8, and 12 days of adulthood, and DHA-TG improved its motility at every age without affecting lifespan. In addition, the treatment promoted antioxidant capacity by enhancing the activity and expression of SOD (superoxide dismutase) in the nematodes. Lastly, as the effect of DHA-TG was lost in the DAF-16 mutant strain, it might be hypothesized that the effects of DHA need DAF-16/FOXO as an intermediary. In brief, DHA-TG exerted a healthspan-promoting effect resulting in both enhanced physical fitness and increased antioxidant defense in aged C. elegans. For the first time, an improvement in locomotive function in aged wild-type nematodes is described following DHA-TG treatment.

Datos de la publicación

ISSN/ISSNe:
2073-4409, 2073-4409

Cells  MDPI

Tipo:
Article
Páginas:
-
PubMed:
37566010
Factor de Impacto:
1,452 SCImago
Cuartil:
Q1 SCImago

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • C. elegans; DAF-16/FOXO; PUFA; aging; antioxidant; cognitive decline; docosahexaenoic acid; healthspan; nematode; omega-3; oxidative stress; physical decline; structured lipids

Proyectos y Estudios Clínicos

MOLECULAR MECHANISMS OF PROTEIN AGGREGATION IN VITRO AND IN VIVO MODELS OF HUNTINGTON DISEASE

Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE

CP11/00090 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2012

MECHAGGRENAMICS. MECHANISMS OF CELL DYSFUNCTION BY AGGREGATION DYNAMICS OF POLYQ-CONTAINING PROTEINS

Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE

322034_MARIE_CURIE_VAZQUEZ_FP7-PEOPLE-2012-CIG . COMISION EUROPEA; ASOCIACION VALENCIANA DE ENFERMEDAD HUNTINGTON . 2012

COMPREHENSIVE, INTEGRATIVE AND GENOMIC APPROACH TO THE UNDERSTANDING AND TREATMENT OF CANCER AND LEUKEMIA.

Investigador Principal: MIGUEL ÁNGEL SANZ ALONSO

PIE13/00046 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2014

ESTRATEGIAS TERAPÉUTICAS CONTRA LA TOXICIDAD PRODUCIDA POR PÉPTIDOS Y RNA CODIFICADOS POR EL ALELO MUTANTE DE HTT EN LA ENFERMEDAD DE HUNTINGTON.

Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE

PI14/00949 . INSTITUTO DE SALUD CARLOS III . 2015

MODELOS DE HÍGADO AISLADO PERFUNDIDO PARA EL RESCATE DE ÓRGANOS Y TRASLACIÓN DE LA TERAPIA GÉNICA EN EL TRASPLANTE: ESCENARIOS HUMANO "EX VIVO" Y PORCINO "IN VIVO"

Investigador Principal: RAFAEL LÓPEZ ANDÚJAR

2017_0270_CRC_LOPEZ . FUNDACION MUTUA MADRILEÑA . 2017

Mecanismos y estrategias terapéuticas en la Enfermedad de Huntington mediante metformina y salicilato.

Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE

PI17/00011 . INSTITUTO DE SALUD CARLOS III . 2018

Estrategia terapéutica contra la enfermedad de Huntington mediante la activación sinergística de AMPK.

Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE

2018_0381_CRC_RAMON ARECES_VAZQUEZ . FUNDACIÓN RAMÓN ARECES . 2019

Tu hospital investiga RRI.

Investigador Principal: ANA ISABEL JUAN ROCH

FCT-18-14018 . FUNDACION ESPAÑOLA PARA LA CIENCIA Y LA TECNOLOGIA . 2019

Randomized, double-blind, placebo-controlled study to evaluate the effect of metformin, an activator of AMPK, on cognitive decline in patients with Huntington's disease. TEMET-HD

Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE

ICI19/00014 . INSTITUTO DE SALUD CARLOS III . 2020

Activación sinérgica de AMPK para detener el progreso de la enfermedad de Huntington

Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE

ACIF/2020/366 . CONSELLERIA DE EDUCACION . 2020

Modulating the activity of genes controlling fat metabolism as a therapeutic strategy in Huntington disease.

Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE

PI20/00114 . INSTITUTO DE SALUD CARLOS III . 2021

Plataforma ISCIII de Biobancos y Biomodelos

Investigador Principal: JOSÉ VICENTE CERVERA ZAMORA

PT20/00179 . INSTITUTO DE SALUD CARLOS III . 2021

ESTUDIO ALEATORIZADO, DOBLE CIEGO, CONTROLADO CON PLACEBO PARA EVALUAR EL EFECTO DE LA METFORMINA, UN ACTIVADOR DE LA AMPK, SOBRE MEDIDAS COGNITIVAS DE PROGRESIÓN EN PACIENTES DE LA ENFERMEDAD DE HUNTINGTON.

Investigador Principal: CARMEN PEIRÓ VILAPLANA

TEMET-HD . 2020

MODFAT-HD-Modulators of fat metabolism as druggable targets to treat Huntington Disease.

Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE

PCI2021-122099-2B . COMISION EUROPEA . 2022

Uso de ubiquibodies in vitro para el tratamiento de distrofias hereditarias de la retina dominantes asociadas a mutaciones en CRX.

Investigador Principal: JOSÉ MARÍA MILLÁN SALVADOR

2022-852-1_CRC_ONCE_MILLAN . ONCE . 2022

Cita

Compartir